Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Decreased by Voya Investment Management LLC

Key Points

• Voya Investment Management LLC reduced its stake in Arrowhead Pharmaceuticals by 40.2% in the first quarter, now holding 32,184 shares valued at $410,000.
• Arrowhead Pharmaceuticals experienced a loss of ($1.26) EPS for the quarter, falling short of analyst estimates, with total revenue reported at $27.77 million.
• The stock currently has an average rating of "Buy" among analysts, with a consensus price target set at $43.14.

Voya Investment Management LLC decreased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 40.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,184 shares of the biotechnology company's stock after selling 21,609 shares during the quarter. Voya Investment Management LLC's holdings in Arrowhead Pharmaceuticals were worth $410,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ARWR. GAMMA Investing LLC grew its holdings in Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the period. CWM LLC raised its stake in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 40.8% during the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 2,132 shares in the last quarter. XTX Topco Ltd purchased a new stake in Arrowhead Pharmaceuticals in the first quarter worth $133,000. Finally, Mackenzie Financial Corp bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $137,000. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $32.80 on Friday. The firm has a market capitalization of $4.53 billion, a P/E ratio of -25.63 and a beta of 1.00. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock has a fifty day moving average price of $22.61 and a 200 day moving average price of $17.51. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $33.73.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the previous year, the company posted ($1.38) earnings per share. Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. B. Riley raised Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Royal Bank Of Canada reduced their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Finally, TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $43.14.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $30.00, for a total value of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. This trade represents a 6.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 40,000 shares of company stock worth $1,025,000 in the last three months. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.